LEO Pharma, a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.
The mission of the partnership is to improve the lives of dermatology patients with access to innovative clinical trials and the launch of new medicines. The partnership will operate under the acronym of PACE, reflecting the requirement to move quickly to address today’s clinical development challenges. It also represents LEO Pharma and ICON’s shared values of Passion, Agility, Communication and Excellence in delivery.
Building on earlier collaboration successes within psoriasis trials, LEO Pharma expect to further strengthen its transformation journey by entering a strategic partnership with ICON. The partnership will leverage both fully outsourced and functional outsourcing models in a tailored and flexible hybrid approach. LEO Pharma plans to achieve the following while remaining a patient centric company:
- Drive efficiencies in clinical trials
- Significant and lean scalability in all areas of expertise within clinical development
- Co-investment within the area of decentralised clinical trials
- Access to a significant number of ICON in-house ancillary services
- Economies of scope and scale
- Access to external data, knowledge & expertise as well as technologies
- A partnership with a company that shares similar core values
“We’ve been exploring several outsourcing models but found a hybrid sourcing model to be the most efficient. Partnering with ICON supports our 2030 strategy as it will help us to bring innovative treatments to patients faster while also supporting a more sustainable business through scalability and flexibility,” said Jörg Möller, Executive Vice President and head of Global R&D at LEO Pharma. “ICON’s wealth of services and leading position in clinical development will support LEO Pharma’s R&D strategy building on driving innovation through partnerships and support staying competitive.”
In supporting LEO Pharma through this partnership, ICON will draw upon a team of over 500 professionals from across its business to deliver tailored solutions, bringing differentiating and enabling capabilities including its laboratories, Accellacare site-network, FIRECREST site management and decentralised clinical trial capabilities to create strategic advantage in how the trials are delivered.
“ICON is delighted to enter this partnership with LEO Pharma that truly takes advantage of our breadth of capability and expertise. We take a flexible and integrated approach when working with our partners, utilising fully outsourced, hybrid and FSP models that complement our partner’s internal capabilities and enable them to achieve their strategic goals. It is also motivating for our employees to be working with a partner that shares our values and has a commitment to improving the lives of patients,” said Steve Cutler, CEO, ICON.
Connect with ICON on LinkedIn: www.linkedin.com/company/icon-plc-2/
Follow @ICON_plc on Twitter: https://twitter.com/ICONplc
Connect with LEO Pharma on LinkedIn: www.linkedin.com/company/leo-pharma
Follow @LEOHealthySkin on Twitter: https://twitter.com/LEOHealthySkin
About ICON plc
ICON is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,100 employees in 111 locations in 53 countries as at December 31, 2022. For further information about ICON, visit: www.iconplc.com.
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,700 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion. Learn more at www.leo-pharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230310005162/en/
+353 87 4066091
Pia Beltrao Hansen
+45 3140 1245